Computer-Aided Selection of Novel Antitumor Drugs for Animal Screening
Louis Hodes · ACS symposium series · 1979
An earlier paper (1) described a method for estimating the probability of activity of compounds. In that report the method was applied to a small set of data for the purpose of comparing the performance to that of more sophisticated pattern recognition methods. The intended application was the large volume of data from the antitumor screening program of the National Cancer Institute (NCI). Early in 1976 a new panel of animal models for screening was adopted. These include mouse colon, breast, and lung tumors; and corresponding human tumor xenografts in athymic mice. Most compounds are required to show activity in an in vivo pre-screen in order to receive the more extensive testing. P388 mouse lymphocytic leukemia was chosen as the pre-screen and, thus, P388 became the logical choice for a trial of the statistical-heuristic method. There were already substantial amounts of P388 data from earlier tests, and roughly 15,000 compounds